{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/viking-therapeutics-vktx/",
 "dataUrl": "https://clearank.com/stock/viking-therapeutics-vktx/data.json",
 "title": "Viking Therapeutics Inc (VKTX) Stock Forecast (2026)",
 "description": "Viking Therapeutics, Inc. (VKTX) stock: Healthcare, Biotechnology. $3.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Viking Therapeutics, Inc. (VKTX)",
 "published": "2026-07-03T09:32:06+00:00",
 "modified": "2026-09-11T11:03:00.47+00:00",
 "generated": "2026-09-11T21:17:02.792Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "VKTX",
  "name": "Viking Therapeutics, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.vikingtherapeutics.com"
 },
 "quote": {
  "price": 32.13,
  "previousClose": 32.7,
  "change": -0.57,
  "changePercent": -1.74,
  "open": 32.5,
  "high": 32.65,
  "low": 31.87,
  "volume": 1711000,
  "averageVolume": 1801220,
  "marketCap": 3748058865,
  "fiftyTwoWeekHigh": 43.15,
  "fiftyTwoWeekLow": 22.959,
  "marketOpen": false,
  "asOf": "2026-09-11T11:02:57.000Z"
 },
 "statistics": {
  "pe": -10.084638924434268,
  "eps": -4.67,
  "dividendYield": 0,
  "beta": 0.679,
  "priceToSales": null,
  "priceToBook": 9.18,
  "revenueTtm": 0,
  "grossMargin": null,
  "returnOnEquity": -0.88852996
 },
 "technicals": {
  "rsi": 39.16,
  "macd": -0.34,
  "sma50": 35.07,
  "sma200": 33.45,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 79,
  "consensus": "Buy",
  "fairValue": 32.13,
  "analystTarget": 95,
  "analystCount": 20,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-11T11:02:57.000Z",
  "priceAtAnalysis": 32.13,
  "volatility": {
   "daily": 2.76,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 31.49,
  "aggressiveEntry": 32.13,
  "stopLoss": 30.18,
  "stopLossPercent": 4.14,
  "targets": [
   33.06,
   34.64,
   36.21
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 19.84,
    "base": 37.66,
    "upside90th": 71.48
   },
   {
    "year": 2028,
    "downside10th": 17.83,
    "base": 44.14,
    "upside90th": 109.24
   },
   {
    "year": 2029,
    "downside10th": 17.05,
    "base": 51.74,
    "upside90th": 156.97
   },
   {
    "year": 2030,
    "downside10th": 16.83,
    "base": 60.64,
    "upside90th": 218.44
   },
   {
    "year": 2031,
    "downside10th": 16.96,
    "base": 71.07,
    "upside90th": 297.85
   },
   {
    "year": 2032,
    "downside10th": 17.34,
    "base": 83.3,
    "upside90th": 400.26
   },
   {
    "year": 2033,
    "downside10th": 17.92,
    "base": 97.64,
    "upside90th": 532.02
   },
   {
    "year": 2034,
    "downside10th": 18.68,
    "base": 114.44,
    "upside90th": 701.01
   },
   {
    "year": 2035,
    "downside10th": 19.62,
    "base": 134.13,
    "upside90th": 917.13
   },
   {
    "year": 2036,
    "downside10th": 20.72,
    "base": 157.22,
    "upside90th": 1192.75
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "VKTX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$32.50",
    "Day Range": "$31.87 to $32.65",
    "Prev Close": "$32.70",
    "Volume": "1.71M",
    "52-Week Range": "$22.96 to $43.15",
    "Market Cap": "$3.75B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis"
   ]
  },
  {
   "id": "financials",
   "title": "VKTX Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, VKTX beat estimates 3 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "VKTX Analysis",
   "text": [
    "Viking Therapeutics' stock is currently trading below its key moving averages, with its price below the 50-day SMA of $35.07 and the 200-day SMA of $33.45. The Relative Strength Index (RSI) is at 39.16, indicating bearish momentum. The MACD is also below its signal line, reinforcing the negative short-term trend. Volume on the latest trading day was slightly below its average, suggesting a lack of strong conviction from buyers at current levels. Key resistance is now seen at the 50-day SMA, while support levels are less defined given the current downtrend.",
    "Positive results from ongoing clinical trials for Viking Therapeutics' drug candidates could significantly boost investor confidence and drive the stock price towards analyst targets.",
    "The median Wall Street price target of $95 represents a 195.7% upside from the current stock price, indicating strong potential for capital appreciation if the company meets expectations.",
    "Recent insider transactions show net selling totaling $23.2 million against only $179.9 thousand in purchases, indicating a moderate sell signal from company insiders.",
    "The stock is trading below its 50-day and 200-day moving averages ($35.07 and $33.45), with RSI below 40, suggesting continued downward pressure in the short term.",
    "The outlook for Viking Therapeutics is cautiously optimistic, driven by strong analyst conviction and a median price target of $95, implying substantial upside from the current $32.13. This target suggests that the market is pricing in significant future growth, likely from the company's drug pipeline. The company's ability to execute on its clinical development and achieve regulatory approvals will be paramount to realizing this potential. However, near-term headwinds exist, including bearish technical indicators and notable insider selling. Investors should monitor upcoming clinical trial results and regulatory updates closely, as positive developments could catalyze a move towards the analyst targets, while setbacks could lead to further downside pressure."
   ],
   "lists": {
    "ProTips": [
     "Monitor upcoming clinical trial data releases for Viking Therapeutics, as positive results are key catalysts for the stock's valuation.",
     "Given the current bearish technical trend, consider waiting for a confirmed upward price momentum or a break above the 50-day SMA before initiating new positions.",
     "The significant insider selling warrants attention; track any future insider transactions for shifts in management sentiment."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Positive Clinical Trial Data",
     "text": "Positive results from ongoing clinical trials for Viking Therapeutics' drug candidates could significantly boost investor confidence and drive the stock price towards analyst targets.",
     "source": "Company Pipeline Updates"
    },
    {
     "type": "Bullish",
     "title": "Analyst Price Target Upside",
     "text": "The median Wall Street price target of $95 represents a 195.7% upside from the current stock price, indicating strong potential for capital appreciation if the company meets expectations.",
     "source": "Wall Street Research"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Recent insider transactions show net selling totaling $23.2 million against only $179.9 thousand in purchases, indicating a moderate sell signal from company insiders.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Momentum",
     "text": "The stock is trading below its 50-day and 200-day moving averages ($35.07 and $33.45), with RSI below 40, suggesting continued downward pressure in the short term.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Viking Therapeutics operates in the Biotechnology sector, which has a median P/E ratio of -6.88 (negative, reflects current losses) and median revenue growth of 8.1%. The company's own revenue growth is not provided, and its EPS is negative (-$4.67), making traditional P/E ratio analysis inapplicable. The lack of positive revenue growth and negative EPS suggest the company is in a growth or development phase, relying on future pipeline success for valuation. The current price of $32.13 does not appear to be supported by current fundamental metrics, but the significant upside potential indicated by analyst targets suggests market expectations are heavily weighted towards future pipeline developments.",
    "Viking Therapeutics' recent earnings reports show a mixed performance. The company reported an EPS of $0.89 in the latest quarter (July 2026), beating estimates by 2.3%, though the stock saw a 1.27% decline. Prior to this, a significant miss occurred in April 2026 with an EPS of -$1.37 against an estimate of -$0.91. While the most recent quarter showed a slight beat, the overall earnings trajectory has been inconsistent, with a substantial miss in Q2 2026 and a beat in Q1 2026. Revenue estimates for upcoming quarters are currently reported as $0.",
    "The primary risks for Viking Therapeutics include the significant insider selling activity, with over $23 million in sales against minimal purchases, signaling a moderate sell signal from management. The stock's current bearish technical momentum, trading below key moving averages, also presents a near-term risk. Also, the company's negative EPS and lack of reported revenue growth indicate a reliance on future pipeline success, which carries inherent clinical and regulatory risks."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "3.75B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-4.67"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "43.15"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "22.96"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Bearish SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($35.07) above the 200-day SMA ($33.45), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "39.16"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.34"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "35.07"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "33.45"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.31",
    "Correlation with Nasdaq 100 (QQQ)": "+0.30",
    "Correlation with Bitcoin (BTC)": "+0.17",
    "Correlation with Gold (XAU)": "+0.08"
   }
  },
  {
   "id": "trade-plans",
   "title": "VKTX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (39.2) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$33.06",
    "TARGET 2": "$34.64",
    "TARGET 3": "$36.21",
    "STOP LOSS": "$30.18"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+1.27%",
    "Average Feb return": "+24.73%",
    "Average Mar return": "-2.93%",
    "Average Apr return": "+1.93%",
    "Average May return": "+11.66%",
    "Average Jun return": "+2.64%",
    "Average Jul return": "-0.32%",
    "Average Aug return": "+3.85%",
    "Average Sep return": "+6.23%",
    "Average Oct return": "+7.00%",
    "Average Nov return": "+0.60%",
    "Average Dec return": "+16.43%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.76%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in VKTX in September 2016 would be worth about $245,267 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VKTX today could grow to about $48,932 by 2036 in the base case, with a bull case near $371,226 and a bear case around $6,450. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "VKTX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $60.64 for VKTX by 2030 in the base case, from $32.13 today (1.9x over 4 years). The downside path ends near $16.83. These are outcomes of a Monte Carlo simulation run on VKTX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using VKTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. VKTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "VKTX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$19.84",
        "$37.66",
        "$71.48"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$17.83",
        "$44.14",
        "$109"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$17.05",
        "$51.74",
        "$157"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$16.83",
        "$60.64",
        "$218"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$16.96",
        "$71.07",
        "$298"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$17.34",
        "$83.30",
        "$400"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$17.92",
        "$97.64",
        "$532"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$18.68",
        "$114",
        "$701"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$19.62",
        "$134",
        "$917"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$20.72",
        "$157",
        "$1,193"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "OSCR Oscar Health, Inc. NYSE $31.84 +0.2361%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $257.30 +0.1245%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "MDT Medtronic NYSE $90.78 -0.9223%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $326.14 -1.26%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $27.78 -0.0360%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.81 +0.3398%",
     "url": "https://clearank.com/stock/neogen-neog/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $607.50 +0.7162%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "ILMN Illumina Inc. NASDAQ $206.28 +2.49%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "EOG vs DVN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/eog-vs-dvn/"
    },
    {
     "text": "SNPS vs CDNS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/snps-vs-cdns/"
    },
    {
     "text": "VUG vs SCHG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-schg/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "VKTX Insider Trading Analysis",
   "facts": {
    "Bought": "$179.9K",
    "Sold": "$23.2M",
    "Insiders": "10",
    "Avg Transaction": "$1.5M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in VKTX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 1, 2024",
       "cells": [
        "MANCINI MARIANNA Chief Operating Officer",
        "Sell",
        "281.4K",
        "$22.1M"
       ]
      },
      {
       "label": "Sep 20, 2024",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "216.1K",
        "$15.3M"
       ]
      },
      {
       "label": "Oct 28, 2024",
       "cells": [
        "ZANTE GREGORY S Chief Financial Officer",
        "Sell",
        "131.7K",
        "$10.1M"
       ]
      },
      {
       "label": "Jan 6, 2025",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "194.5K",
        "$8.3M"
       ]
      },
      {
       "label": "Jan 5, 2026",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "233.4K",
        "$7.7M"
       ]
      },
      {
       "label": "Aug 19, 2024",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "112.9K",
        "$7.4M"
       ]
      },
      {
       "label": "Feb 8, 2024",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "269.1K",
        "$7.2M"
       ]
      },
      {
       "label": "Jul 30, 2024",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "115.9K",
        "$6.7M"
       ]
      },
      {
       "label": "May 3, 2024",
       "cells": [
        "ZANTE GREGORY S Chief Financial Officer",
        "Sell",
        "66.8K",
        "$5.0M"
       ]
      },
      {
       "label": "Jul 29, 2026",
       "cells": [
        "LIAN BRIAN Chief Executive Officer",
        "Sell",
        "148.5K",
        "$4.9M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Viking+Therapeutics%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Viking Therapeutics' (VKTX) stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Viking Therapeutics' stock price is projected to be $60.64 in 2030 under a base case scenario. The downside projection is $16.83, while the upside projection reaches $218.44. These figures represent statistical outcomes and are not definitive price targets."
  },
  {
   "question": "Is VKTX stock a buy right now?",
   "answer": "Viking Therapeutics (VKTX) is rated a 'Buy' by Wall Street analysts, with a consensus score of 79 out of 100. The median analyst price target is $95, suggesting a potential upside of 195.7% from the current price of $32.13."
  },
  {
   "question": "What are the main risks facing Viking Therapeutics?",
   "answer": "Key risks for VKTX include significant insider selling totaling over $23 million, bearish technical indicators with the stock trading below its 50-day and 200-day moving averages ($35.07 and $33.45), and the company's current negative EPS and lack of reported revenue growth."
  },
  {
   "question": "How has Viking Therapeutics performed in recent earnings reports?",
   "answer": "Viking Therapeutics reported an EPS beat in its latest quarter (July 2026) at $0.89 versus an estimate of $0.87, but the stock declined. Previous quarters showed a significant EPS miss in April 2026 and a beat in March 2026, indicating inconsistent earnings performance."
  },
  {
   "question": "What is the technical outlook for VKTX stock?",
   "answer": "The technical outlook for VKTX is currently bearish, with the stock trading below its 50-day and 200-day moving averages ($35.07 and $33.45) and exhibiting bearish momentum according to the RSI and MACD indicators."
  },
  {
   "question": "How does VKTX compare to its sector averages?",
   "answer": "Viking Therapeutics operates in the Healthcare sector, which has a median P/E of -6.88 and median revenue growth of 8.1%."
  },
  {
   "question": "What is the consensus rating for Viking Therapeutics stock?",
   "answer": "The consensus rating for Viking Therapeutics (VKTX) among Wall Street analysts is 'Buy', with a total of 20 analysts covering the stock. The overall Wall Street score is 79 out of 100."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$31.84",
    "change": "+0.2361%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$257.30",
    "change": "+0.1245%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$90.78",
    "change": "-0.9223%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$326.14",
    "change": "-1.26%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$27.78",
    "change": "-0.0360%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.81",
    "change": "+0.3398%",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$607.50",
    "change": "+0.7162%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$206.28",
    "change": "+2.49%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "EOG vs DVN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/eog-vs-dvn/"
   },
   {
    "ticker": "SNPS vs CDNS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/snps-vs-cdns/"
   },
   {
    "ticker": "VUG vs SCHG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-schg/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "KEYS",
    "text": "Keysight Technologies, Inc.",
    "url": "https://clearank.com/stock/keys-stock-analysis/"
   },
   {
    "ticker": "BRO",
    "text": "Brown & Brown Inc.",
    "url": "https://clearank.com/stock/bro-stock-analysis/"
   },
   {
    "ticker": "SYY",
    "text": "Sysco Corp.",
    "url": "https://clearank.com/stock/syy-stock-analysis/"
   },
   {
    "ticker": "FIS",
    "text": "Fidelity National Information Services, Inc.",
    "url": "https://clearank.com/stock/fis-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "SWKS",
    "text": "↑ 9.79%",
    "url": "https://clearank.com/stock/skyworks-solutions-swks/"
   },
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 9.39%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.23%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↑ 8.90%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   },
   {
    "ticker": "HUT",
    "text": "↑ 8.77%",
    "url": "https://clearank.com/stock/hut-stock-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RGNX",
    "text": "REGENXBIO",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "text": "Recursion",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "VRTX",
    "text": "Vertex Pharmaceuticals",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/viking-therapeutics-vktx.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/viking-therapeutics-vktx.png",
     "width": "1280",
     "height": "720",
     "caption": "Viking Therapeutics Inc (VKTX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/viking-therapeutics-vktx/",
        "name": "Viking Therapeutics Inc (VKTX) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#webpage",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/",
     "name": "Viking Therapeutics Inc (VKTX) Stock Forecast (2026)",
     "datePublished": "2026-07-03T09:32:06+00:00",
     "dateModified": "2026-09-11T11:03:00+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/viking-therapeutics-vktx.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Viking Therapeutics Inc (VKTX) Stock Forecast (2026)",
     "datePublished": "2026-07-03T09:32:06+00:00",
     "dateModified": "2026-09-11T11:03:00+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Viking Therapeutics, Inc. (VKTX) stock: Healthcare, Biotechnology. $3.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Viking Therapeutics Inc (VKTX) Stock Forecast (2026)",
     "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/viking-therapeutics-vktx.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/viking-therapeutics-vktx/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Viking Therapeutics, Inc. (VKTX)",
   "tickerSymbol": "VKTX",
   "url": "https://clearank.com/stock/viking-therapeutics-vktx/",
   "description": "AI-powered financial analysis for Viking Therapeutics, Inc. (VKTX) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 32.13,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Viking Therapeutics' (VKTX) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Viking Therapeutics' stock price is projected to be $60.64 in 2030 under a base case scenario. The downside projection is $16.83, while the upside projection reaches $218.44. These figures represent statistical outcomes and are not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is VKTX stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Viking Therapeutics (VKTX) is rated a 'Buy' by Wall Street analysts, with a consensus score of 79 out of 100. The median analyst price target is $95, suggesting a potential upside of 195.7% from the current price of $32.13."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Viking Therapeutics?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for VKTX include significant insider selling totaling over $23 million, bearish technical indicators with the stock trading below its 50-day and 200-day moving averages, and the company's current negative EPS and lack of reported revenue growth."
     }
    },
    {
     "@type": "Question",
     "name": "How has Viking Therapeutics performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Viking Therapeutics reported an EPS beat in its latest quarter (July 2026) at $0.89 versus an estimate of $0.87, but the stock declined. Previous quarters showed a significant EPS miss in April 2026 and a beat in March 2026, indicating inconsistent earnings performance."
     }
    },
    {
     "@type": "Question",
     "name": "What is the technical outlook for VKTX stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The technical outlook for VKTX is currently bearish, with the stock trading below its 50-day and 200-day moving averages and exhibiting bearish momentum according to the RSI and MACD indicators."
     }
    },
    {
     "@type": "Question",
     "name": "How does VKTX compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Viking Therapeutics operates in the Healthcare sector, which has a median P/E of -6.88 and median revenue growth of 8.1%."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating for Viking Therapeutics stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for Viking Therapeutics (VKTX) among Wall Street analysts is 'Buy', with a total of 20 analysts covering the stock. The overall Wall Street score is 79 out of 100."
     }
    }
   ]
  }
 ]
}